Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)

Healthcare · Pharmaceuticals · NSE · Updated 1 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹241.05 ↑ 2.95% (1Y)

🎯 Key Takeaways

Jagsonpal Pharmaceuticals is transitioning from a mature domestic player into a growth-oriented entity with strategic inorganic expansion, marked by its acquisition of Aequitas Healthcare and a clear FY28 revenue target of ₹500 crore. The company is leveraging strong cash flows and profitability to fund growth while maintaining disciplined capital allocation through buybacks and dividends.
Revenue grew 28.1% QoQ to ₹82 in Q1FY27.
⚠️ Integration risks associated with the Aequitas Healthcare acquisition, particularly in scaling operations and achieving projected EBITDA targets withi

Market Cap

₹1,587

P/E Ratio

35.5

P/B Ratio

6.62

ROE

19.0%

ROCE

25.8%

Debt/Equity

0.00

Div Yield

1.66%

Promoter

69.0%

✨ Ask AI About JAGSNPHARM 📊 Interactive Charts

📖 The Story

Jagsonpal Pharmaceuticals is transitioning from a mature domestic player into a growth-oriented entity with strategic inorganic expansion, marked by its acquisition of Aequitas Healthcare and a clear FY28 revenue target of ₹500 crore. The company is leveraging strong cash flows and profitability to fund growth while maintaining disciplined capital allocation through buybacks and dividends. It is now focused on scaling its critical care segment and expanding in high-margin therapeutic areas, signaling a shift toward sustainable, scalable growth.

📰 What's Happening

In Q1 FY27, Jagsonpal reported 9% revenue growth to Rs.82 crores and 22% net profit growth to Rs.13 crores, driven by operational improvements and a 40% premium share buyback of Rs.40 crores. The company completed the acquisition of an 85% stake in Aequitas Healthcare for Rs.20.8 crores, strengthening its critical care portfolio. Management highlighted that Aequitas is expected to contribute Rs.10 crores in EBITDA within two years, and emphasized organic growth through brand building and hospital cross-selling of products like Maintane and Indocap. The cash balance post-buyback stood at Rs.170 crores, supporting continued strategic investments.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	74	73	64	82
Operating Profit	14	14	9	15
OPM %	18.9%	19.0%	13.8%	18.4%
Net Profit	13	11	9	13
EPS	₹1.88	₹1.67	₹1.25	₹2.00

The company has demonstrated consistent profitability growth, with net profit rising 22% quarter-on-quarter to Rs.13 crores in Q1 FY27, while operating margins improved to 18.4%. Revenue growth has stabilized around 7-9% quarterly, supported by both organic momentum and the integration of Aequitas Healthcare. Despite modest revenue base, EBITDA margins are expanding, with EBITDA at Rs.19 crores in Q1 FY27, reflecting improved operational efficiency. The strong cash generation and balance sheet strength provide a foundation for sustained investment in growth initiatives without compromising financial stability.

🔮 Management Outlook & What's Next

Management has provided forward-looking guidance targeting ₹500 crore revenue by FY28 and Rs.10 crores EBITDA from Aequitas Healthcare within two years. They emphasized continued focus on strategic growth pillars, inorganic expansion, and sustainable value creation. The company also underscored its commitment to governance improvements and disciplined capital allocation, including enhanced shareholder returns through dividends and buybacks. These targets and commitments reflect confidence in long-term growth prospects and scalable operations.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	13	13	13	13
Reserves	184	226	240	263
Borrowings	10	0	9	8
Total Liabilities	258	278	299	317
Fixed Assets	10	94	8	7
Investments	0	0	0	0
Total Assets	258	278	299	317

The balance sheet shows a strong cash position of Rs.170 crores post-buyback in Q1 FY27, up from Rs.1,907 million in FY26, indicating robust liquidity. There are no borrowings, and equity has remained stable around Rs.13 crores, with reserves growing from Rs.226 to Rs.263 crores over the past year. This suggests the company is funding its expansion through retained earnings and cash reserves rather than debt, reflecting a conservative and self-sustaining capital structure. The absence of debt and growing reserves support financial resilience amid sectoral and operational transitions.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+55
Investing	-45
Financing	-12
Net Cash Flow	-2

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	67.5%	67.4%	67.9%	69.0%
FII	2.1%	2.1%	2.4%	2.3%
DII	0.1%	0.1%	0.2%	0.6%
Public	21.1%	21.2%	20.7%	19.3%
# Shareholders	24,653	24,895	26,264	24,181

Promoter holding has slightly declined from 69.05% in Q1FY27 to 67.89% in Q4FY26, while institutional ownership (FII) has remained stable around 2.1-2.4%, and DII holdings have increased marginally from 0.09% to 0.62%. The number of public shareholders has grown from 24,181 to 26,264, indicating rising retail participation. There are no signs of significant promoter selling or institutional exit, and the stable institutional presence suggests confidence in the company’s trajectory. The growing shareholder base may reflect increasing market interest in its growth narrative.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.69 L Cr	38.8	18.7%	14.6%	0.05
DIVISLAB	2.45 L Cr	83.9	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.4	15.1%	25.7%	1.76
ZYDUSLIFE	1.16 L Cr	25.9	16.8%	16.6%	0.43
CIPLA	1.14 L Cr	33.9	13.2%	9.8%	0.01
LAURUSLABS	1.03 L Cr	94.1	20.8%	20.6%	0.45
LUPIN	99,585	17.6	27.9%	24.7%	0.26
MANKIND	99,078	48.5	13.9%	12.7%	0.38
DRREDDY	97,240	30.1	10.1%	8.4%	0.17
AUROPHARMA	97,239	26.4	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Integration risks associated with the Aequitas Healthcare acquisition, particularly in scaling operations and achieving projected EBITDA targets within two years. 2. Margin pressure in the hospital segment, as highlighted in investor takeaways, could impact overall profitability if not addressed. 3. Regulatory and pricing pressures in the pharmaceutical sector may constrain growth despite strong cash flows. 4. Over-reliance on a few key products like Maintane and Indocap for cross-selling exposes the company to product-specific demand fluctuations.

📋 Recent Filings

🧠 Analyst's Read

Jagsonpal is executing a clear transformation strategy centered on growth through acquisition and portfolio expansion, supported by strong cash flows and shareholder-friendly capital allocation. Investors should monitor the pace of integration at Aequitas Healthcare and the sustainability of margin performance in the hospital segment, as these will be critical to achieving long-term growth targets.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on JAGSNPHARM

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JAGSNPHARM files new disclosures

Track JAGSNPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JAGSNPHARM — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd